Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA is a research paper published in PROTEOMICS - CLINICAL APPLICATIONS (2021). On theSindex it has a DataRank of 0. It has been cited 9 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01‐CA164024
NCI NIH HHS
Grant: R01 CA164024
NCI NIH HHS
Grant: U10 CA098543
NCI NIH HHS
Grant: U24 CA196173
NCI NIH HHS
Grant: U10 CA098413
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: U10 CA180899
NCI NIH HHS
Grant: U10 CA180886
National Institutes of Health
Grant: 2U10CA180899-06
Children's Oncology Group Statistics and Data Center
National Institutes of Health
Grant: 3U10CA180886-01S1
COG NCTN Network Group Operations Center
National Institutes of Health
Grant: 5U10CA098413-08
Children's Oncology Group Statistics and Data Center Grant
National Institutes of Health
Grant: 3U10CA098543-03S1
Childrens Oncology Group Chairs Grant
National Institutes of Health
Grant: 1R01CA164024-01A1
Identifying Cell Stress Proteins that Predict Clinical Response in Pediatric AML
National Institutes of Health
Grant: 3U24CA196173-09S1
COG Biobanking Support
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals